Rapt therapeutics stock trial#

The plaform is easy-to-use and offers access to a wealth of research and learning tools. We chose CIBC Investor's Edge for this category because it offers special pricing for students (and for active traders). We chose Interactive Brokers for this category because it offers extensive trading capabilities and provides access to advanced trading tools to help savvy traders in their investing journey.

In addition, students can take advantage of special pricing for making trades if they have a CIBC Student Bank account. We chose CIBC Investor's Edge for this category because it offers an easy to use, user-friendly interface and provides a number of learning resources to help you get acquainted with the platform. With no account fee, the mobile app is clean and intuitive to use. We chose Wealthsimple Trade for this category because it offers commission-free trading.

We encourage you to compare stock platforms to find one that's best for your particular budget and goals. You can learn more about our methodology here. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.We evaluate stock trading platforms against a range of metrics that include fees, ease of use, available securities and advanced tools to meet specific investor needs. compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. We may also receive compensation if you click on certain links posted on our site. We may receive compensation from our partners for placement of their products or services. While we are independent, the offers that appear on this site are from companies from which receives compensation. and changed its name to RAPT Therapeutics, Inc.ДЇ is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. The company was formerly known as FLX Bio, Inc. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Rapt therapeutics stock trial#

Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. , a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. This would suggest that RAPT Therapeutics's shares are less volatile than average (for this exchange). The market (NASDAQ average) beta is 1, while RAPT Therapeutics's is 0.1382. A popular way to gauge a stock's volatility is its 'beta'.Д«eta is a measure of a share's volatility in relation to the market. Over the last 12 months, RAPT Therapeutics's shares have ranged in value from as little as $14.89 up to $43.26. We're not expecting RAPT Therapeutics to pay a dividend over the next 12 months. TTM: trailing 12 months RAPT Therapeutics share dividends

Our pick for active traders.TradeStation is our top pick for this category because it offers a wealth of tools and data for active traders, along with paper trading and educational resources.Plus, thereвЂ™s no minimum to open an account. SoFi also has financial advisers on staff to help talk you through trading strategies and financial goals - for free. We chose SoFi for this category because it offers commission-free stocks and an easy-to-use mobile app thatвЂ™s highly-rated by customers. ItвЂ™s a unique option best suited to investors who want some control over their portfolio, but arenвЂ™t experienced enough or donвЂ™t have the time to actively manage a portfolio. M1 is our pick because it lets you choose your own stocks, but offers automated portfolio rebalancing to manage your risk level. We evaluate stock trading platforms against a range of metrics that include fees, ease of use, available securities and advanced tools to meet specific investor needs.